Navigation Links
Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Date:8/18/2008

- Transaction Includes $10 Million in Upfront Fees and Milestones -

DALLAS, Aug. 18 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI Pharma, Amgen and Genentech. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radiation treatments, and has already received marketing allowance from the U.S. Food and Drug Administration. Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon commercialization of MuGard. Milestone expects to launch MuGard in the US early in the first quarter of 2009.

"We are pleased to have Milestone as our North American partner for MuGard," said Jeffrey B. Davis, President & CEO of Access. "Milestone has assembled a team of very experienced pharmaceutical executives with a great track record of commercial success in oncology supportive care, including experience with the oral mucositis market and related chronic dry mouth market. We are excited and confident that this team of experienced executives will successfully launch and commercialize MuGard."

"MuGard is an important product for Milestone as it gives us a tremendous near term product around which to launch and further grow our sales team. We believe there is a significant un-met medical need for MuGard with solid commercial sales potential," stated Eric Loukas, CEO of Milestone. "Our seasoned commercial team is excited about the potential for MuGard in the oral mucositis mark
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
2. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
3. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
4. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
5. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
6. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
7. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
8. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
9. A Perfect Storm Threatens Patient Access to Specialty Medical Care
10. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
11. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
(Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
Breaking Biology Technology:Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... ... U.S. House Science and Technology Committee , ... Washington (Vocus) January 27, 2010 -- DuPont Applied BioSciences Vice ... Representatives Science and Technology Committee that the U.S. Department of Energy (DOE) Advanced Research ...
... , CAMBRIDGE, Mass. and OXFORD, England ... Institute and Oxford BioMedica (LSE: OXB) announced today the extension ... The extended collaboration, which is funded by the Muscular Dystrophy ... gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies ...
... , , WILMINGTON, Del. , Jan. ... fourth quarter 2009 earnings news release contained an extra comma ... following statement: "Due to strong pension fund performance, the company ... per share, lower than originally anticipated."  The foregoing statement should ...
Cached Biology Technology:DuPont Science Leader Urges U.S. House Committee to Continue Federal Investment in Transformative, Clean Energy Technologies 2ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 2ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 3ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 4ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 5
(Date:7/10/2014)... a whole fresh avocado with either an orange-colored tomato ... (alpha- and beta-carotene) absorption and conversion of these carotenoids ... new research (1) published in The Journal ... is involved in reproductive health and growth promotion; helps ... antioxidant properties. Provitamin A carotenoids, like alpha- and beta-carotene, ...
(Date:7/9/2014)... PA, July 10, 2014 Inflammatory diseases can ... patient, complicating treatment because a medication effective for ... example is the anti-arthritic medication dexamethasone, which alleviates ... A study in the August issue of ... effects of a new class of anti-arthritic drugs, ...
(Date:7/9/2014)... to switch out one gene for another in a ... science fiction to reality within this decade. As with ... hope of fixing disease-causing genes in humans, for example--as ... have put one of those concerns to rest: using ... occurrence of mutations in the cells. The new results ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... CINCINNATI An experimental procedure successfully tested in obese ... weight-loss surgery, researchers report online in Endocrinology . ... used a catheter to re-direct the flow of bile ... the same metabolic and weight-loss benefits as bariatric surgeries ...
... In a comparison of the effect of different dosages ... raised and maintained plasma concentrations within a range recommended ... maintained plasma concentrations within a lower range recommended by ... the May 1 issue of JAMA , a ...
... methanol to formaldehyde - this reaction is the starting ... catalysts made of gold particles, formaldehyde could be produced ... Just how the mysterious gold catalyst works has been ... Ruhr-Universitt Bochum in a cooperation project. In the international ...
Cached Biology News:Study finds possible alternative to bariatric weight loss surgery 2Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Mysterious catalyst explained 2
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: